Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 8,378 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: serum sample Clear all
Completed Not applicable Interventional Results available

HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer

NCT02165605
View directory record Official record
Conditions
Breast Cancer
Interventions
HylaCare, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 28, 2026, 7:46 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

NCT02898259
View directory record Official record
Conditions
B Cell Lymphoma, Lymphoma
Interventions
Ixazomib, Lenalidomide, Rituximab
Drug
Lead sponsor
Brian Hill
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 28, 2026, 7:46 AM EDT
Active, not recruiting Phase 2 Interventional

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

NCT03546686
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab, Core Biopsy/Cryoablation, Breast Surgery, Ipilimumab, Nivolumab
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
4
States / cities
Los Angeles, California • Columbus, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 28, 2026, 7:46 AM EDT
Recruiting Phase 2 Interventional

Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer

NCT07402473
View directory record Official record
Conditions
HER2-positive Early-stage Breast Cancer
Interventions
Trastuzumab, Pertuzumab, Docetaxel, Carboplatin
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Long Branch, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 2 Interventional Results available

Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer

NCT00392769
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Cetuximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 2 Interventional Results available

SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors

NCT01661283
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma
Interventions
everolimus, bevacizumab
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 1 Interventional

Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

NCT00390156
View directory record Official record
Conditions
Unspecified Adult Solid Tumor
Interventions
bevacizumab, cyclophosphamide, imatinib
Biological · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 28, 2026, 7:46 AM EDT
Completed No phase listed Observational

Serum Brain Natriuretic Peptide Levels and Pulmonary Hypertension in Pediatric Sickle Cell Patients

NCT01023451
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 28, 2026, 7:46 AM EDT
Terminated Phase 2 Interventional

MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer

NCT00602329
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, fluorouracil, leucovorin calcium, oxaliplatin
Biological · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 1 Interventional

Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer

NCT00064129
View directory record Official record
Conditions
Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 28, 2026, 7:46 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

NCT02096042
View directory record Official record
Conditions
Leukemia
Interventions
Brentuximab Vedotin, 5-Azacytidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 28, 2026, 7:46 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

NCT03997786
View directory record Official record
Conditions
Moderate-to-severe Chronic Plaque Psoriasis
Interventions
Tildrakizumab, Placebo, Etanercept
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
6 Years to 215 Months
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
5
States / cities
Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 1 Interventional

Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

NCT00598169
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, carboplatin, dexamethasone, etoposide, ifosfamide, polymerase chain reaction, western blotting
Biological · Drug · Genetic
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 2 Interventional Results available

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

NCT01216683
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, Bendamustin, bortezomib, lenalidomide
Biological · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
227
States / cities
Greenbrae, California • Salinas, California • Stanford, California + 158 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Results available

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

NCT01621490
View directory record Official record
Conditions
Advanced Melanoma, Metastatic Melanoma
Interventions
Nivolumab, Ipilimumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Chicago, Illinois • Lutherville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation

NCT00455013
View directory record Official record
Conditions
Disorder Related to Renal Transplantation
Interventions
Thymoglobulin, Belatacept, Sirolimus, Tacrolimus, Mycophenolate Mofetil (MMF)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 28, 2026, 7:46 AM EDT
Completed No phase listed Observational

Biomarkers of Renal Dysfunction in Neuroblastoma Survivors

NCT03947346
View directory record Official record
Conditions
Neuroblastoma Survivors
Interventions
Urine sample
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 2 Interventional Results available

Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients

NCT00393861
View directory record Official record
Conditions
Neoplasms, Germ Cell and Embryonal
Interventions
Bevacizumab and Oxaliplatin
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 28, 2026, 7:46 AM EDT
Withdrawn Not applicable Interventional

Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

NCT02053727
View directory record Official record
Conditions
Rheumatoid Arthritis, Chronic Hepatitis B
Interventions
Abatacept, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 1 Interventional

Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

NCT01274624
View directory record Official record
Conditions
KRAS Mutant Metastatic Colorectal Cancer
Interventions
REOLYSIN®, Irinotecan, Leucovorin, Fluorouracil (5-FU), Bevacizumab
Biological · Drug
Lead sponsor
Oncolytics Biotech
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 28, 2026, 7:46 AM EDT
Completed Phase 3 Interventional Results available

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

NCT02525861
View directory record Official record
Conditions
Alpha1-antitrypsin Deficiency
Interventions
GLASSIA
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 28, 2026, 7:46 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)

NCT00604461
View directory record Official record
Conditions
Mesothelioma
Interventions
Carboplatin, Bevacizumab and Pemetrexed
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 28, 2026, 7:46 AM EDT
Not listed Phase 2 Interventional

Phase II Study in Patients With Operable Breast Cancer

NCT00518583
View directory record Official record
Conditions
Breast Cancer
Interventions
Pegylated Liposomal Doxorubicin (Doxil)
Drug
Lead sponsor
Aptium Oncology Research Network
Network
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
9
States / cities
Burbank, California • Los Angeles, California • Palm Springs, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 28, 2026, 7:46 AM EDT
Recruiting Phase 1 Interventional

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

NCT07257419
View directory record Official record
Conditions
Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy
Interventions
Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine, Thiotepa, Mesna, Melphalan, Filgrastim, CliniMACS System
Drug · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 28, 2026, 7:46 AM EDT